2025
Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series.
Greenberg A, Shahriari M, Cameron M, Payette M, Dasilva D, Damiani G, Herman E, Eminger L, Issa N, Rodriguez A, Del Rosso J, Kang Y, Cohen J, Bunick C. Tralokinumab as a Therapeutic Alternative for Dupilumab-associated Arthralgia in Atopic Dermatitis: A Multi-center Case Series. The Journal Of Clinical And Aesthetic Dermatology 2025, 18: 16-19. PMID: 40538523, PMCID: PMC12175839.Peer-Reviewed Original ResearchInvestigator's Global AssessmentAdverse eventsFood and Drug AdministrationAtopic dermatitisInterleukin-4Alternative therapiesSwitching to alternative therapiesSurface area of involvementDiscontinuation of dupilumabDiscontinuation of treatmentT cell populationsChronic inflammatory skin conditionMulti-center case seriesUnited States Food and Drug AdministrationStates Food and Drug AdministrationBody surface areaOptimal clinical outcomesInflammatory skin conditionAD signsTargeting interleukins 4Area of involvementSystemic treatmentT cellsCase seriesClinical outcomesAddressing unmet needs for patients with erectile dysfunction: a narrative review of topical therapies
Brock G, Hellstrom W, Giraldi A, Honig S. Addressing unmet needs for patients with erectile dysfunction: a narrative review of topical therapies. Sexual Medicine 2025, 13: qfaf021. PMID: 40356742, PMCID: PMC12066416, DOI: 10.1093/sexmed/qfaf021.Peer-Reviewed Original ResearchTopical therapyErectile dysfunctionClinical studiesTopical alprostadilSexual Medicine Society of North AmericaAlternative therapiesPhosphodiesterase type 5 inhibitorsEffective topical therapyOver-the-counter agentsUnited States Food and Drug AdministrationStates Food and Drug AdministrationTreatment of patientsFood and Drug AdministrationNitric oxide donorHydro-alcoholic gelSite of actionClinically significant improvementAcceptability of treatmentHeterogeneity of studiesErectile functionTopical agentsED therapyTreatment optionsIdeal medicationPDE5iSynergistic Antibacterial Effects of Plant Extracts and Essential Oils Against Drug-Resistant Bacteria of Clinical Interest
Shahin H, Baroudi M, Dabboussi F, Ismail B, Salma R, Osman M, Omari K. Synergistic Antibacterial Effects of Plant Extracts and Essential Oils Against Drug-Resistant Bacteria of Clinical Interest. Pathogens 2025, 14: 348. PMID: 40333114, PMCID: PMC12030331, DOI: 10.3390/pathogens14040348.Peer-Reviewed Original ResearchConceptsFractional inhibitory concentration indexAntibacterial effect of plant extractsListeria monocytogenes</i>Drug-resistant bacteriaDrug-resistant microorganismsEmergence of drug-resistant microorganismsSynergistic antibacterial effectCombat antimicrobial resistanceMicrodilution assayBacterial strainsCombination of essential oilsAntibacterial efficacyTested essential oilsAntimicrobial resistanceEssential oilEffects of plant extractsCrude extractEucalyptus globulus</i>Treated with antimicrobialsAntibacterial effectPlant extractsAntibioticsTherapeutic strategiesAlternative therapiesClinical interest
2024
0568 Promoting Shared Decision Making with a Novel Self-Monitoring Program for Veterans with Obstructive Sleep Apnea
Mak S, Ghadimi S, Der-Mcleod E, Moore V, Naeem S, Chohan M, Zeidler M, Ash G, Fung C. 0568 Promoting Shared Decision Making with a Novel Self-Monitoring Program for Veterans with Obstructive Sleep Apnea. Sleep 2024, 47: a243-a243. DOI: 10.1093/sleep/zsae067.0568.Peer-Reviewed Original ResearchObstructive sleep apneaObstructive sleep apnea treatmentSleep apneaShared decision makingPAP therapyOSA treatmentAirway pressurePAP treatmentSleep centerTreatment optionsTreatment successDaytime sleepinessSleep cliniciansAlternative therapiesPatientsPulse oximetryTherapyTherapy effectsSpO2 dataApneaTreatmentQuality improvement projectPAPSpO2Patient preference elicitation
2023
What are the benefits and drawbacks of statins in carotid artery disease? A perspective review
Said S, Dardik A, Chaar C. What are the benefits and drawbacks of statins in carotid artery disease? A perspective review. Expert Review Of Cardiovascular Therapy 2023, 21: 763-777. PMID: 37994875, PMCID: PMC11493559, DOI: 10.1080/14779072.2023.2286011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCarotid artery diseaseCarotid artery stenosisSide effectsArtery diseaseArtery stenosisAlternative therapiesSymptomatic carotid artery stenosisAtherosclerotic carotid artery diseaseMultiple international guidelinesAcute ischemic strokeImpact of statinsGenetic polymorphismsStatin side effectsWarrants close monitoringDrug of choiceSerious side effectsMechanism of statinStatin therapyCarotid revascularizationIschemic strokePCSK9 inhibitorsLipid controlStroke incidencePatient selectionClinical efficacy
2022
Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor
Han R, Yang H, Ling C, Lu L. Tiliroside suppresses triple-negative breast cancer as a multifunctional CAXII inhibitor. Cancer Cell International 2022, 22: 368. PMID: 36424626, PMCID: PMC9685933, DOI: 10.1186/s12935-022-02786-6.Peer-Reviewed Original ResearchTriple-negative breast cancerBreast cancerTNBC cellsBreast cancer treatmentNegative breast cancerCaspase-3 activity analysisExpression levelsSpheroid formation assayFurther RT-PCRTNBC patientsTumor burdenEarly recurrencePoor prognosisAggressive subtypeChemotherapy responseAlternative therapiesPreclinical studiesTNBC progressionMouse modelTherapeutic implicationsPreclinical experimentsSurvival rateTherapeutic useClinic practiceLevel assaysThe Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.
McQuaid JR, Buelt A, Capaldi V, Fuller M, Issa F, Lang AE, Hoge C, Oslin DW, Sall J, Wiechers IR, Williams S. The Management of Major Depressive Disorder: Synopsis of the 2022 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline. Annals Of Internal Medicine 2022, 175: 1440-1451. PMID: 36122380, DOI: 10.7326/m22-1603.Peer-Reviewed Original ResearchConceptsClinical practice guidelinesMajor depressive disorderVeterans AffairsDepressive disorderPractice guidelinesDefense Clinical Practice GuidelineJoint clinical practice guidelineManagement of MDDTrustworthy clinical practice guidelinesUse of telemedicineMedicine's tenetsPharmacologic managementGuideline panelAlternative therapiesGRADE systemKey recommendationsPrior recommendationsClinical stakeholdersImportant new evidenceDisordersSelect recommendationsDepartmentGuidelinesManagementRecommendationsInternational guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn
Lieberman L, Lopriore E, Baker JM, Bercovitz RS, Christensen RD, Crighton G, Delaney M, Goel R, Hendrickson JE, Keir A, Landry D, La Rocca U, Lemyre B, Maier RF, Muniz‐Diaz E, Nahirniak S, New HV, Pavenski K, dos Santos M, Ramsey G, Shehata N, Guidelines F. International guidelines regarding the role of IVIG in the management of Rh‐ and ABO‐mediated haemolytic disease of the newborn. British Journal Of Haematology 2022, 198: 183-195. PMID: 35415922, PMCID: PMC9324942, DOI: 10.1111/bjh.18170.Peer-Reviewed Original ResearchConceptsRole of IVIGIntravenous immunoglobulinExchange transfusionHaemolytic diseaseSafety of IVIGRed blood cell transfusionBlood cell transfusionDuration of hospitalizationSeverity of anemiaEvidence-based recommendationsHigh-quality studiesCell transfusionPrompt treatmentBilirubin levelsSignificant morbidityAlternative therapiesIntensive phototherapyNeurocognitive outcomesManagement of RhInternational guidelinesTransfusionNewbornsDiseasePhototherapyInternational panel
2021
Dietary supplements and alternative therapies for obesity: A Perspective from The Obesity Society’s Clinical Committee
Kidambi S, Batsis JA, Donahoo WT, Jastreboff AM, Kahan S, Saunders KH, Heymsfield SB. Dietary supplements and alternative therapies for obesity: A Perspective from The Obesity Society’s Clinical Committee. Obesity 2021, 29: 1095-1098. PMID: 34159756, DOI: 10.1002/oby.23189.Peer-Reviewed Original ResearchTiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis
Han R, Yang H, Lu L, Lin L. Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis. Scientific Reports 2021, 11: 8626. PMID: 33883691, PMCID: PMC8060393, DOI: 10.1038/s41598-021-88133-7.Peer-Reviewed Original ResearchConceptsLiver cancer developmentLiver cancerCancer developmentLiver cancer cell linesCD133 expression levelsAnti-proliferation effectQuantitative reverse transcription PCRCancer cell linesCancer deathTHLE-3THLE-3 cellsAlternative therapiesReverse transcription-PCREffective therapyFatal causeNC groupTherapeutic implicationsInvasion assaysTherapeutic useClinic practiceELISA kitHigher anti-proliferation effectColony formationTranscription-PCRAnticancer efficacy
2020
TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making
Bataillard E, Harris W, El-Galaly T, Kwan A, Henneges C, Paulson J, Nielsen T. TRAIL (Tolerability of R-CHOP in Aggressive non-Hodgkin Lymphoma): A Predictive Algorithm to Support Clinical Decision-Making. Blood 2020, 136: 34-35. DOI: 10.1182/blood-2020-134904.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaCurrent equity holderArea under the receiver operating characteristic curveAverage relative dose intensityCharlson Comorbidity IndexBone marrow lymphocytesR-CHOPAnti-CD20Progressive diseaseWithdrawal of cyclophosphamideAdverse eventsMarrow lymphocytesDiffuse large B-cell lymphoma patientsLong-term event free survivalTreatment of diffuse large B-cell lymphomaClinical trialsDose intensity of cyclophosphamideProportion of Th cellsTreated with R-CHOPF. Hoffmann-La RocheHigh risk of relapseLarge B-cell lymphomaAlternative therapiesR-CHOP treatmentRelative dose intensityIncidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin
Maraj I, Hummel JP, Taoutel R, Chamoun R, Workman V, Li C, Tran L, DelVecchio A, Howes C, Akar JG. Incidence and determinants of QT interval prolongation in COVID‐19 patients treated with hydroxychloroquine and azithromycin. Journal Of Cardiovascular Electrophysiology 2020, 31: 1904-1907. PMID: 32485061, PMCID: PMC7300464, DOI: 10.1111/jce.14594.Peer-Reviewed Original ResearchComplementary and Alternative Medicine for Functional Gastrointestinal Disorders.
Deutsch JK, Levitt J, Hass DJ. Complementary and Alternative Medicine for Functional Gastrointestinal Disorders. The American Journal Of Gastroenterology 2020, 115: 350-364. PMID: 32079860, DOI: 10.14309/ajg.0000000000000539.Peer-Reviewed Original ResearchConceptsFunctional GI disordersFunctional gastrointestinal disordersGI disordersGastrointestinal disordersAlternative therapiesIrritable bowel syndromeQuality of lifeFunctional dyspepsiaBowel syndromeTreatment algorithmTherapeutic resultsTreatment strategiesAlternative medicinePatientsDisordersComplex disorderGastroenterologistsTherapySignificant numberNauseaVomitingDyspepsiaSyndromeGastroenterologySymptoms
2019
Cost‐Related Medication Nonadherence Among Older Adults: Findings From a Nationally Representative Sample
Chung GC, Marottoli RA, Cooney LM, Rhee TG. Cost‐Related Medication Nonadherence Among Older Adults: Findings From a Nationally Representative Sample. Journal Of The American Geriatrics Society 2019, 67: 2463-2473. PMID: 31437309, DOI: 10.1111/jgs.16141.Peer-Reviewed Original ResearchConceptsCost-related medication nonadherenceNational Health Interview SurveyMedication nonadherenceHealth Interview SurveyOlder adultsRisk factorsMultivariable logistic regression analysisInterview SurveyModifiable risk factorsLow-cost medicationsMedication therapy managementLogistic regression analysisChronic disease subgroupsLow socioeconomic levelCross-sectional analysisNationally Representative SampleFemale sexSubgroup analysisAlternative therapiesTherapy managementNonadherenceDisease subgroupsFunctional limitationsYounger agePrescription drugsFirst in Human Experience with Direct Sodium Removal Using a Zero Sodium Peritoneal Solution
Rao V, Turner J, Mahoney D, Griffin M, Asher J, Ivey-Miranda J, Gomez N, Finkelstein F, Testani J. First in Human Experience with Direct Sodium Removal Using a Zero Sodium Peritoneal Solution. Journal Of Cardiac Failure 2019, 25: s7-s8. DOI: 10.1016/j.cardfail.2019.07.027.Peer-Reviewed Original ResearchStandard PD solutionHeart failurePeritoneal dialysisPD solutionsSignificant discomfortPeritoneal solutionsSodium removalHF animal modelsMethods 10 patientsSafety/tolerabilitySecondary efficacy endpointsPrimary endpointEfficacy endpointAdverse eventsBlood pressureSerum sodiumAlternative therapiesPeritoneal fluidPlasma glucosePlasma potassiumUltrafiltration volumeAnimal modelsIntraperitoneal volumeDSR groupVital signsManagement of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic
Sinha C, Bakshi N, Ross D, Krishnamurti L. Management of Chronic Pain in Adults Living With Sickle Cell Disease in the Era of the Opioid Epidemic. JAMA Network Open 2019, 2: e194410. PMID: 31125105, PMCID: PMC6632133, DOI: 10.1001/jamanetworkopen.2019.4410.Peer-Reviewed Original ResearchConceptsSickle cell diseaseOpioid epidemicOpioid usePain managementChronic painAlternative therapiesCell diseaseAfrican American race/ethnicityDisease controlVaso-occlusive painPain medication useChronic pain managementSickle cell clinicCurrent opioid epidemicRace/ethnicityOpioid dosingOpioid dosageOpioid prescriptionsAdult patientsMedian ageMedication usePersistent painComprehensive careMAIN OUTCOMEPainOutcomes of upper tract urothelial cancer managed non-surgically.
Syed JS, Nguyen KA, Suarez-Sariemento A, Leung C, Casilla-Lennon M, Raman JD, Shuch B. Outcomes of upper tract urothelial cancer managed non-surgically. Canadian Journal Of Urology 2019, 26: 9699-9707. PMID: 31012833.Peer-Reviewed Original ResearchConceptsUpper tract urothelial cancerCharlson-Deyo scoreMedian overall survivalOverall survivalTumor gradeCox proportional hazards regression modelProportional hazards regression modelsNational Cancer DatabaseKaplan-Meier methodHazards regression modelsHigh-grade tumorsGovernment health insuranceDefinitive surgeryDefinitive therapyGreater comorbidityOlder patientsMedian agePatient demographicsWorse survivalUrothelial cancerGrade tumorsAlternative therapiesCancer DatabaseOS differenceRadiation therapyThe nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?
Syed J, Nguyen K, Javier-Desloges J, Leapman M, Raman J, Shuch B. The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance? Journal Of Clinical Oncology 2019, 37: 485-485. DOI: 10.1200/jco.2019.37.7_suppl.485.Peer-Reviewed Original ResearchUpper tract urothelial cancerMedian overall survivalOverall survivalTumor gradeCox proportional hazards regression modelProportional hazards regression modelsNational Cancer DatabaseKaplan-Meier methodHazards regression modelsHigh-grade tumorsGovernment health insuranceDefinitive surgeryDefinitive therapyOlder patientsPatient demographicsMedian ageWorse survivalUrothelial cancerGrade tumorsAlternative therapiesCancer DatabaseOS differenceRadiation therapyPatientsSurvival analysis
2017
Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Cavallari L, Lee C, Beitelshees A, Cooper-DeHoff R, Duarte J, Voora D, Kimmel S, McDonough C, Gong Y, Dave C, Pratt V, Alestock T, Anderson R, Alsip J, Ardati A, Brott B, Brown L, Chumnumwat S, Clare-Salzler M, Coons J, Denny J, Dillon C, Elsey A, Hamadeh I, Harada S, Hillegass W, Hines L, Horenstein R, Howell L, Jeng L, Kelemen M, Lee Y, Magvanjav O, Montasser M, Nelson D, Nutescu E, Nwaba D, Pakyz R, Palmer K, Peterson J, Pollin T, Quinn A, Robinson S, Schub J, Skaar T, Smith D, Sriramoju V, Starostik P, Stys T, Stevenson J, Varunok N, Vesely M, Wake D, Weck K, Weitzel K, Wilke R, Willig J, Zhao R, Kreutz R, Stouffer G, Empey P, Limdi N, Shuldiner A, Winterstein A, Johnson J, Network I. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. JACC Cardiovascular Interventions 2017, 11: 181-191. PMID: 29102571, PMCID: PMC5775044, DOI: 10.1016/j.jcin.2017.07.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedClinical Decision-MakingClopidogrelCytochrome P-450 CYP2C19Drug ResistanceFemaleHumansMaleMiddle AgedPatient SelectionPercutaneous Coronary InterventionPharmacogeneticsPharmacogenomic TestingPharmacogenomic VariantsPlatelet Aggregation InhibitorsPrasugrel HydrochloridePredictive Value of TestsRisk AssessmentRisk FactorsTicagrelorTime FactorsTreatment OutcomeUnited StatesConceptsGenotype-guided antiplatelet therapyCYP2C19 genotype-guided antiplatelet therapyCYP2C19 loss-of-function allelesLoss-of-function allele carriersPercutaneous coronary interventionAdverse cardiovascular eventsAntiplatelet therapyCardiovascular eventsAlternative therapiesRandomized studyLoss-of-function allelesAllele carriersCoronary interventionClinical implementationMonths of percutaneous coronary interventionInverse probability of treatment weightingInverse probabilityPercutaneous coronary intervention patientsProbability of treatment weightingAcute coronary syndromeAlternative antiplatelet therapyClopidogrel effectCoronary syndromeCox regressionClinical genotypingBeliefs About a Complementary and Alternative Therapy–Based Chronic Pain Management Program for a Medicaid Population
Donovan E, Ranney M, Patry E, McKenzie M, Baird J, Green T. Beliefs About a Complementary and Alternative Therapy–Based Chronic Pain Management Program for a Medicaid Population. Pain Medicine 2017, 18: 1805-1816. PMID: 28398544, DOI: 10.1093/pm/pnx051.Peer-Reviewed Original ResearchConceptsChronic pain programPain programRhode Island MedicaidTemporary pain reliefChronic pain management programPain management programHigher emergency departmentPatient-provider relationshipQuality of lifePain reliefComplicated patientsComplementary therapiesEmergency departmentPatient interviewsAlternative therapiesMedicaid populationProvider interviewsPatientsTreatment approachesEnough visitsReceiving ServicesTherapyDeductive thematic analysisQualitative interview-based studyThematic analysis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply